Abstract: Provided herein are, inter alia, CAR-T cell compositions targeting CD6, CD19, and/or an IL-13R, and methods useful for treating autoimmune diseases and cancer.

Abstract: Methods and compositions discussed herein allow for preventing or treating type 1 diabetes (T1D) including directing the breakdown of insulin mRNA.

Abstract: Provided herein are, inter alia, anti-CD6 antibody-growth factor complexes including an anti-CD6 antibody portion bound to a growth factor protein (e.g., EGF) through a linker, which may be cleavable by a protease (e.g., diabetic microenvironment specific protease). The compositions provided herein are, inter alia, useful for the treatment of autoimmune diseases (e.g., type I diabetes).

Abstract: Provided herein are, inter alia, CD6 targeting CAR-T cell compositions and methods useful for treating autoimmune diseases (e.g., Type I diabetes).

Abstract: Provided herein are, inter alia, methods, compositions, and kits for culturing and improving the quality of islet cells. Included are compositions and kits for the ex vivo culture of islets or islet cells as well as methods of making and using the same. Isolated and cultured islets and islet cells are also provided.

Abstract: The present invention relates to the identification of novel peptides derived from aberrant proteins involved in Type 1 Diabetes mellitus (T1D), also known as defective ribosomal products (DRiPs). In particular the invention relates to epitopes present in DRiPs of the human preproinsulin (PPI) mRNA, its representative peptides and the use thereof in diagnosis, prevention and/or treatment of T1D. Moreover, the inventions relate to antibodies and antisera against the identified epitopes and the use thereof in the diagnosis of T1D.

Abstract: The invention provides a purified human 38 kD beta cell antigen consisting of an intrinsic transmembrane protein of insulin secretory granules of beta cells lying in pancreatic islets of Langerhans, which protein contains an epitope recognized by T cell clone 1C6 (ECACC No. 1C6 90050301). The antigen may be used to diagnose diabetes in a patient.

Abstract: The present invention identified novel epitopes from the insulin B chain which is embodied in methods and means for diagnostics and treatment of type 1 diabetes. The epitopes were found in a peptide comprising a fragment of the human insulin B chain. Using HLA-A2 tetramers having the peptide of the invention cytotoxic T-cells were found in peripheral blood cells samples from healthy individuals. The invention demonstrates that these autoreactive CTL directed against insulin B chain are able to destroy insulin producing beta-cells. Moreover, a significant proportion of cytotoxic T-cells from islet transplant recipients with recurrent autoimmunity and loss of insulin production recognized this peptide or analogue thereof. The peptide has a high affinity for the HLA-A2 allele, in particular HLA-A*0201. Based on the novel epitopes according to the invention, diagnostic and therapeutic methods and medicaments for the prevention or treatment of type 1 diabetes are provided.